Kato H, Tamai K, Magaya T, Nagai M, Noguchi H, Suehiro Y, Torigoe T
Gan No Rinsho. 1985 May;31(6 Suppl):594-9.
The present study shows the clinical values of SCC-Antigen, a subfraction of TA-4, for the management of squamous cell carcinoma. Serum SCC-Antigen levels of 2.0 ng/ml was designated as the cut-off value. Serum antigen levels were positive in 53.5% of cervical squamous cell carcinoma, and the changes in serum antigen levels reflected the disease progress. The antigen was also positive in cancer of vagina, vulva, lung or esophagus. To detect the early cervical cancer, flow cytometric analysis of the exfoliative cells was conducted, using anti-TA-4 serum, which was found to be particularly useful for the detection of early disease. It was concluded that the use of SCC-Antigen would be promising in clinical care.
本研究显示了TA-4的一个亚组分SCC抗原在鳞状细胞癌治疗中的临床价值。血清SCC抗原水平2.0 ng/ml被指定为临界值。53.5%的宫颈鳞状细胞癌患者血清抗原水平呈阳性，且血清抗原水平的变化反映了疾病进展。该抗原在阴道癌、外阴癌、肺癌或食管癌中也呈阳性。为检测早期宫颈癌，使用抗TA-4血清对脱落细胞进行了流式细胞术分析，发现该方法对早期疾病的检测特别有用。得出结论，SCC抗原在临床护理中具有应用前景。
